MGX (Metagenomi) Pre-Tax Income : $-83.57 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Metagenomi Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Metagenomi's pretax income for the three months ended in Dec. 2024 was $-24.61 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-83.57 Mil. Metagenomi's pretax margin was -255.94%.

During the past 4 years, Metagenomi's highest Pretax Margin was -134.57%. The lowest was -8823.87%. And the median was -199.16%.

Metagenomi Pre-Tax Income Historical Data

The historical data trend for Metagenomi's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi Pre-Tax Income Chart

Metagenomi Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

-21.44

-41.02

-60.23

-83.57

Metagenomi Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial						-16.57	-25.15	-12.94	-20.88	-24.61

Competitive Comparison of Metagenomi's Pre-Tax Income

For the Biotechnology subindustry, Metagenomi's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metagenomi's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Metagenomi's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Metagenomi Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Metagenomi's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-88.901	+	-9.392	+	0	+	14.722	+	0
	=	-83.57

Metagenomi's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-20.623	+	-7.179	+	0	+	3.196	+	-3.5527136788005E-15
	=	-24.61

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-83.57 Mil.

Metagenomi (NAS:MGX) Pre-Tax Income Explanation

Metagenomi's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-24.606	/	9.614
	=	-255.94%

During the past 4 years, Metagenomi's highest Pretax Margin was -134.57%. The lowest was -8823.87%. And the median was -199.16%.

Metagenomi Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Metagenomi's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Metagenomi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608

Website

https://metagenomi.co

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.